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Background: patients with 22q11.2DS may develop severe thrombocytopenic 67 
purpura (ITP) and hemolytic anemia (AIHA). There are no reliable predictors for the 68 
development of hematologic autoimmunity (HA) in these patients. 69 
Objective: describe the peculiar B and T subpopulations defects in 22q11DS 70 
patients that have developed HA and test if these defects precede the development 71 
of HA. 72 
Methods: We performed a case-control multicenter study. Patients with HA were 73 
compared with a control population of 22q11.2DS without hematologic autoimmunity 74 
(non-HA). A complete immunological evaluation was performed at diagnosis and at 75 
last follow-up including extensive T and B phenotype.  76 
Results: Immunophenotype at last follow-up was available in 23 HA and 45 non-HA 77 
patients. HA patients had significantly decreased percentage of naïve CD4+ cells, 78 
(26,8% vs 43,2%, p=0,003) and recent thymic emigrants (48,6% vs 80,5%, p=0,046); 79 
decreased class-switched B cells (2,0% vs 5,9% p=0,04) and increased naive B cells 80 
(83,5% vs 71,4%, p=0,02); increased CD16+/56+ both in absolute number (312 vs 81 
199, p=0,009) and percentage (20,0% vs 13,0%, p=0,03). 82 
Immunophenotype was performed in 36 patients (11 HA and 25 non-HA) at 83 
diagnosis. Odds ratio (OR) of immune cytopenia were estimated for both CD4 naïve 84 
≤30% (OR 14.0 p=0.002) and for SMB ≤2% (OR 44.0 p=0.01). The estimated 85 
survival curves reached statistical significance respectively p=0.0001 and p=0.002. 86 
Conclusion: Among 22q11.2DS patients those with HA have characteristic 87 
lymphocytes anomalies that appear considerably before HA onset. Systematic 88 
immunophenotyping of 22q11.2DS patients at diagnosis is advisable for early 89 

















Highlights box: 92 
1. What is already known about this topic?  93 
• Some patients with 22q11.2DS may develop severe hematologic 94 
autoimmunity, it is impossible to predict which patients will develop this severe 95 
complication. 96 
2. What does this article add to our knowledge?  97 
• 22q11.2 DS patients with hematologic autoimmunity have peculiar B and T 98 
immunophenotype anomalies, the anomalies precede the onset of 99 
autoimmunity and may be used for risk stratification. 100 
3. How does this study impact current management guidelines? 101 
• Extensive B and T immunophenotyping is helpful in all 22q11.2 DS patients at 102 
diagnosis. Patients with CD4 naïve ≤30% or Switched Memory B cells ≤2% 103 
are at risk of developing severe hematologic autoimmunity. 104 
 105 
Key words: autoimmune cytopenia, thrombocytopenic purpura, hemolytic anemia, 106 
22q11.2 Deletion Syndrome, DiGeorge Syndrome, B immunophenotype, T 107 
immunophenotype, NK cells, CD4 naïve cells, switched memory B cells 108 
Abbreviations: 109 
22q11DS: 22q11.2 deletion syndrome 110 
ITP: Idiopathic thrombocytopenic purpura  111 
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PID: primary immunodeficiencies 113 
HA: hematological autoimmunity 114 
IPINet: Italian Primary Immunodeficiency Network 115 

















Treg: regulatory T cells 117 
RTE: Recent Thymic Emigrants 118 
SMB: switched memory B cells 119 
CVID: common variable immunodeficiency 120 
MA: multivariate analysis 121 


















Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common 124 
microdeletion disease in humans, with a prevalence of 1:4000 to 1:6000 1-2; the 125 
deletion is most frequently associated to Di-George syndrome (Online Mendelian 126 
Inheritance in Man [OMIM] number, 188400) and velocardiofacial syndrome (OMIM 127 
number, 192430). Usually, the 22q11.2DS is caused by a de novo heterozygous 128 
deletion of approximately 2.5 Mb in length between low-copy repeats (LCR22) A and 129 
D. Less frequently, the syndrome is the result of deletions between LCR22 A and B, 130 
between B and D, or between C and D3. 131 
While the majority (90%) of patients share the same deletion the phenotypic 132 
expression of 22q11DS is widely variable, with over 190 features reported, among 133 
which the most frequent are congenital heart disease, velopharyngeal insufficiency 134 
and cleft palate, immune disorders, feeding difficulties, and hypocalcemia secondary 135 
to hypoparathyroidism4. 136 
The spectrum of immune deficiency ranges from nearly normal immune function to 137 
T-negative severe combined immunodeficiency (SCID). The majority of patients 138 
displays an intermediate form of immune disorder with T-cell lymphopenia more 139 
evident in the early age5,6, decreased naïve and increased memory CD4+ cells, 140 
reduced T-cell receptor (TCR) repertoire6,7 and impaired T-cell function8. 141 
Furthermore, patients with 22q11.2DS may exhibit hypogammaglobulinemia with 142 
defective response to pneumococcal polysaccharide9,10, decreased CD27+ memory 143 
B cells11,12, increased CXCR4+ circulating follicular helper T cells12,13, low natural 144 

















Another hallmark of 22q11DS patients is the increased risk of autoimmune diseases 146 
such as thrombocytopenic purpura (ITP), hemolytic anemia (AIHA), thyroiditis and 147 
arthritis4. The development of autoimmunity is possibly a consequence of immune 148 
dysregulation as it has been proven in patients with other primary 149 
immunodeficiencies (PID). In particular T-cell PIDs are especially prone to develop 150 
hematological autoimmunity (HA)16. 151 
In this paper we have compared the immunophenotype of 22q11DS patients with HA 152 
(ITP and/or AIHA) with other 22q11DS patients without HA in order to understand if 153 
the former group has a distinctive immunological hallmark. Then, we tested the 154 
hypothesis that these immunological hallmarks may precede HA and therefore may 155 
be used as reliable predictors for this serious complication.  156 
Methods 157 
Italian Primary Immunodeficiency Network (IPINet) 22q11DS National Registry is a 158 
web-based application for the collection of clinical and laboratory data of 22q11DS 159 
patients4. Launched in May 2005, it consists in a secure database, compliant to 160 
International Conference on Harmonisation for Good Clinical Practice guidelines and 161 
European regulations. From 2006 to 2018, 16 Italian centers have registered 162 
retrospective and prospective data of 22q11DS patients. Clinical diagnosis was 163 
confirmed by fluorescence in situ hybridization 22 or molecular methods (multiplex 164 
ligation-dependent probe amplification 22 or comparative genomic hybridization 165 
microarray for 22q11.2 microdeletion).  166 
In the context of the IPINet 22q11DS National Registry we selected all the patients 167 

















22q11DS patients without hematologic autoimmunity (non-HA group), randomly 169 
selected.  170 
All del22q11 patients of the Italian registry are assigned a specific anonimous 171 
alfanumeric code when their data are entered in the DB. Using the alfanumeric code 172 
we extracted through a random electronic generator (www.random.org) 45 patient in 173 
the whole non-HA patients of the DB. The random assignment was made by a 174 
blinded examinator. Afterwards the alfanumeric code was used to detect the 175 
anagraphical data and caring physician of each patient.  176 
Clinical and immunologic data sets (complete blood count, serum immunoglobulin 177 
levels, lymphocyte subsets) were extrapolated from the registry. A specific case 178 
report form was elaborate to confirm the registry data and to collect details about 179 
lymphocyte immunophenotype. All the patients provided written informed consent. 180 
The study was approved by the local ethics committees. 181 
Lymphocyte specific population were defined as follows. Regarding T cells: 182 
CD4+CD45RA+ naïve helper T cells, CD4+CD45R0+ activated/memory helper T cells, 183 
CD4+CD45R0+CXCR5+ circulating follicular helper T cells (cTFHs), 184 
CD4+CD25+CD127lowFOXP3+ regulatory T cells (Treg) (all expressed as percentage 185 
of CD4+ T cells); CD4+CD45RA+CD31+ Recent Thymic Emigrants (RTEs) 186 
(expressed as percentage of naïve CD4+ T cells); and CD8+CD27+CD28+ naïve 187 
cytotoxic T cells (expressed as percentage of CD8+ T cells). B cells subsets were 188 
subdivided as CD38++IgM++ transitional B cells, CD27-IgM+IgD+ naïve B cells, 189 
CD27+IgM+IgD+ IgM memory B cells, CD27+IgM-IgD- switched memory B (SMB) 190 
cells, and CD21lowCD38low B cells; all B cell subpopulations are expressed as 191 

















The presence of peculiar lymphocyte subpopulation anomalies in the HA group, in 193 
the respect of the non-HA group, was tested firstly considering the 194 
immunophenotype at last follow-up and after that considering the immunophenotype 195 
at 22q11DS diagnosis. Any subpopulation reaching statistical significance in the 196 
comparison between HA and non-HA group at diagnosis was considered as a 197 
possible predictor of HA development in 22q11DS patients. Using cut-offs defined 198 
according to previous work on the stratification of patients with common variable 199 
immunodeficiency (CVID)17,18 we estimated the odds ratio (OR) of HA development. 200 
In order to define if the candidate predictors were independently associated with HA 201 
development a multivariate analysis (MA) was performed, in the MA analysis age 202 
and gender were included as well. 203 
Finally Kaplan-Meier curves were calculated for all the candidate predictors using the 204 
same cut-offs17,18. 205 
Statistical analysis was performed using IBM SPSS Statistics 20.0 and GraphPad 206 
Prism 6.0. The differences between groups were analyzed using Mann-Whitney U 207 
test for continuous data, and Fisher’s exact test for categorical data. All tests were 208 
two tailed and the significance was set at P ≤ 0.05. Survival curves were estimated 209 
with Kaplan-Meier model and compared with Mantel-Cox test, significance for 210 
survival curves was set at P ≤ 0.05.  211 
Results 212 
HA and non-HA patients have similar clinical features 213 
At January 2018 a total of 358 patients were registered on IPINet 22q11DS National 214 
Registry, with follow-up data available for 294. Global prevalence of autoimmunity 215 

















collected demographic, clinical and laboratory data of 23 HA and 45 non-HA 217 
patients; among HA patients, 16 had ITP and 2 AIHA; 5 patients were affected by 218 
both (Evans Syndrome). Table 1 shows clinical and laboratory features of enrolled 219 
patients. There was no statistical difference in median age at the time of 22q11DS 220 
diagnosis between HA and non-HA. In the case group the mean delay between 221 
22q11DS diagnosis and HA development was 7.9 years. 222 
Table2 provides a comparison of demographic and clinical features of HA and non-223 
HA patients. At follow-up HA patients were significantly older (18.0 vs 14.0 years, 224 
p=0.015) and frequently had persistent hypocalcemia (45.4% vs 17.8%, p=0.016). 225 
None of the other clinical features examined (renal, otorhinolaryngological-ENT, 226 
epilepsy, orthopedic, gastroenterological, cardiac, thymic anatomy or thymectomy 227 
related to cardiac surgery) differed between HA and non-HA groups. The rate of 228 
respiratory recurrent infections, severe infections and the frequency of non-229 
hematological autoimmunity (thyroiditis, arthritis, psoriasis) showed no difference. 230 
HA patients have specific immunophenotypic alterations 231 
Immunophenotype at last follow-up was available in all 68 patients. 232 
No difference in CD4+ total cell count was found between HA and non-HA groups. 233 
HA patients had significantly decreased percentage of naïve CD4+ cells, (26.8% vs 234 
43.2%, p=0.003) and RTEs (48.6% vs 80.5%, p=0.046), with increased memory 235 
CD4+ cells (74.0% vs 55.5%, p=0.001). No difference between HA and non-HA 236 
patients was found in the frequencies of naïve cytotoxic T cells (41.4% vs 49.6%), 237 
Treg (3.9% vs 5.9%), and cTFHs (16.0% vs 13.5%). (Figure1A)  238 
Furthermore, HA patients had decreased class-switched memory B cells (SMB) 239 

















CD21low (9.9% vs 2.4%, p=0.018) (Figure1B). Finally, non-HA patients had increased 241 
CD3-CD16+/56+ NK cells as absolute number (312 vs 199 cells per microliter, 242 
p=0.009) and percentage (20.0% vs 13.0%, p=0.029) (Figure1C). No difference has 243 
been found between HA and non-HA in transitional B cells (7.6% vs 9.4%) and in 244 
IgM Memory B cells (9.8% vs 8.3%).  245 
Naïve CD4+ cells and SMB cells are predictive of development of HA 246 
Immunophenotype at diagnosis was available in 36 patients (11 HA and 25 non-HA). 247 
The age at immunophenotype was not different between groups. 248 
HA patients had significantly decreased percentage of naïve CD4+ cells (29.0% vs 249 
51.0%, p=0.021) and decreased SMB (1.7% vs 4.3%, p=0.015); at the time of 250 
diagnosis NK number and percentage did not differ between HA and non-HA groups.  251 
We therefore estimated the OR of immune cytopenia development based on the 252 
following cut-offs: ≤30% for CD4 naïve and ≤2% for SMB. Cut-offs were identified by 253 
comparison with previous work on the stratification of patients with common variable 254 
immunodeficiency (CVID) 17,18. The OR was 14.0 (2.6-74.6; p=0.002) for CD4 naïve 255 
≤30% group, while for SMB ≤2% group the OR was 44,0 (2.2-98.3; p=0.010). 256 
In the MA both predictors confirmed their predictivity with a p=0.008 for CD4 naïve 257 
(OR 1.8-55.9) and p=0.022 for SMB (OR 1.4-88.7), sex and age at diagnosis were 258 
not associated with HA development. 259 
Survival curves were estimated for both subpopulations using the same cut-offs. All 260 
curves reached statistical significance respectively of p=0.0001 for CD4+ naïve 261 


















In this study we report the immunological findings in 23 HA 22q11DS patients, the 264 
largest cohort described so far in literature. Our data, based upon the Italian registry, 265 
show that HA affects 8% of patients with 22q11.2DS, the appearance of autoimmune 266 
disease is usually 8 years after the 22q11DS diagnosis. HA patients have an almost 267 
complete demographical and clinical overlap compared to non HA patients, making 268 
almost impossible for the physician to predict the development of this complication.  269 
Nevertheless, our follow-up data shows that HA patients have specific 270 
immunophenotypic alterations. The absolute count and percentage value of CD4+ T 271 
cells, which is known to be generally reduced in 22q11.2DS patients compared with 272 
healthy subject 7, do not differ within HA and non-HA subjects. Conversely, we find a 273 
significantly decreased percentage of CD45RA+ naïve and CD31+ RTE T helper 274 
cells, confirming some previous observations 19,20.  275 
Overall our findings suggest a defective thymic output, which is known to be 276 
associated to autoimmunity in several PIDs. The mechanisms that link both 277 
phenomena are still unclear, but certain key pathways have been described in 278 
various PID: a reduced TCR repertoire diversity, a homeostatic IL-7 driven 279 
proliferation of T lymphocytes, and a lack of naturally occurring regulatory T cells 280 
(nTregs)21. Indeed, an intra-thymic defect has also been suggested as a possible 281 
explanation of autoimmunity in 22q11.2DS through incomplete negative selection or 282 
compromised AIRE expression22.  283 
It should be underlined that in our cohort HA patients have a greater incidence of 284 
persistent hypocalcemia suggesting, as another previous study23, the association 285 
between hypoparathyroidism and defective T cell immunity, and linking these 286 
alterations to a defective common organogenesis; indeed an association between 287 

















However, in our cohort the two groups do not differ for thymic anatomy nor for 289 
thymectomy related to cardiac surgery, suggesting that this association could not be 290 
explained solely by a bare anatomic defect. 291 
In effect, immunophenotypic alterations in HA patients are not confined to T cells. In 292 
particular, we observed a significant reduction of class-switched memory B cells 293 
(SMB) and NK cells. SMB are generated in the germinal centers of lymph-nodes by 294 
interaction with their cognate IL-21 expressing TFH cells. Reduced capacity of 295 
generating effective SMB cells is a hallmark of several PIDs, like common variable 296 
immunodeficiency (CVID) spectrum disorders, reflecting in some cases an intrinsic 297 
alteration in THF function17. Previous works underlined that 22q11.2DS adult 298 
patients exhibit a reduction of SMB cells and a decrease rate of somatic 299 
hypermutation, while circulating T follicular helper (cTFH) cells are present at higher 300 
percentages at all ages and display a more activated phenotype 12,13. Indeed, in our 301 
cohort both HA and non-HA patients have increased percentages of cTFH, and the 302 
subjects with higher cTFH values have more severe autoimmune manifestations 303 
(ITP+AIHA) (data not shown). Nevertheless, the overall difference between cTFH in 304 
HA and non-HA do not reach the statistical significance. Definitely, our data are in 305 
lines with an aberrant germinal center function, although it is impossible to establish 306 
whether this defect is ascribable primarily to cTFH cells or instead intrinsic to B cells. 307 
Reduction of both NK number and percentage is an intriguing issue. NK are mostly 308 
innate immunity, extra-thymic derived cells, whereby alteration in its number or 309 
function cannot be a direct consequence of an inadequacy of thymic environment. 310 
The role of NK cells in autoimmune disease has been evaluated in animal models, 311 
but only a few studies, mainly descriptive, have demonstrated NK alterations in 312 

















22q11.2DS patients display a functional defect of NK direct cytolytic and antibody-314 
dependent cell-mediated cytotoxicity due to haploinsufficiency of CRKL gene, 315 
included in the typical deleted region 15. These findings, however, have not been 316 
related to development of autoimmunity. The association of reduced NK numbers 317 
and HA suggests the involvement of a pathway independent from thymic function, 318 
maybe related to an intrinsic lymphocyte defect. 319 
Overall our data at follow-up shows that HA patients exhibit a distinctive 320 
immunophenotypic hallmark. To exclude that the mentioned anomalies were due to 321 
the difference of age between HA and non-HA patients or to possible ongoing 322 
treatment we compared the immunophenotype at 22q11DS diagnosis. Interestingly 323 
some peculiar anomalies of HA immunophenotype were present even at diagnosis, 324 
suggesting that HA should be considered a peculiar complication of 22q11DS 325 
patients with a more severe immunological phenotype rather than a cause of it.  326 
The most prominent result of this study is the prognostic value of these 327 
immunophenotypic alterations. Analyzing prospectively the data from a long follow-328 
up period, we demonstrated that reduced levels of naïve CD4+ and SMB cells are 329 
already present at diagnosis and are strong predictor of HA development. This 330 
finding may represent a critical point in the clinical management of 22q11.2DS 331 
patients. We suggest to clinicians to use lymphocyte immunophenotype to stratify 332 
patient at diagnosis, in order to offer a more personalized follow-up and to early 333 
diagnose potentially severe complications such AIHA and PTI. In particular, we 334 
recommend to utilize CD4+CD45RA+ naïve helper T cells percentage, which is a 335 
simple and reliable test and is an extremely good marker of HA development. When 336 
B lymphocytes subtyping is available SMB analysis increases the predictivity and 337 

















In conclusion our study highlights that, among 22q11.2DS patients, those with HA 339 
have characteristic anomalies regarding T, B and NK cells; these anomalies appear 340 
considerably before HA onset, therefore systematic immunophenotyping of 341 
22q11.2DS patients at diagnosis is advisable for early identification of patients at risk 342 
for this severe complication. In view of the evident immunological features 343 
characterizing this subgroup of patients, it is conceivable that further pathogenetic 344 
mechanisms might be involved with respect to the remaining patients with 345 
22q11.2DS. We are therefore conducting an in-depth genetic investigation in this 346 
specific group of patients with peculiar features to identify possible new genetic 347 
determinants of immune impairment in 22q11.2DS. 348 
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Table and figures 427 
Table1: clinical and laboratory features of enrolled HA patients. ND: Not Defined; 428 
Hypocalcemia: A absent, T transitory, P persistent; ENT: Ears Nose and Throat; 429 
CAKUT: Congenital Anomalies of the Kidneys and of the Urinary Tract; JIA: Juvenile 430 
idiopathic arthritis; HA: Hematological Autoimmunity; ITP: Idiopathic 431 
Thrombocytopenic Purpura; AIHA: Autoimmune Hemolytic Anemia; CS: 432 
corticosteroids; IVIG: intravenous immunoglobulin; RTX: Rituximab; MMF: 433 
mycophenolate. *None of the patient was splenectomized 434 
Table2: comparison of demographic and clinical features of HA and non-HA 435 
patients. ENT: Ears Nose and Throat; CAKUT: Congenital Anomalies of the Kidneys 436 
and of the Urinary Tract; JIA/RA: Juvenile idiopathic arthritis/Rheumatoid Arthritis. 437 
Figure1: Comparison of lymphocyte subpopulations between patients with 438 
hematological autoimmunity (grey box, HA) and patients without hematological 439 
autoimmunity (white box, non-HA). A. CD4 naïve % of CD4+CD3+ cells, RTE % of 440 
CD4 naïve cells and cTFH % of CD4 memory cells. B. Naïve B cells, Switched 441 
Memory B cells and CD21Low cells % of CD19+ cells. C. Peripheral % of total 442 
lymphocytes and absolute number of CD3-CD16+CD56+ NK cells. *P < 0.05 and **P 443 
< 0.01. 444 
Figure2:  Probability of free survival event as a function of the CD4 naïve T helper 445 
cells levels (A) and of switched memory B cells (B). The event was defined as the 446 
onset of hematologic autoimmunity either thrombocytopenic purpura (ITP) or 447 
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 HA non-HA p-value 
Female 39 % 51 % 0.44 
Median age (years) 18.0 14.0 0.02 
Abnormal Thymus 
(Hypoplastic/Absent) 
69.7 % 70.0 % 1.00 
Persistent Hypocalcemia 45.4 % 17.8 % 0.02 
ENT Anomalies 36.4 % 57.7 % 0.10 
Cardiopathy 60.7 % 64.4 % 0.80 
Cardiosurgery 43.5 % 46.7 % 1.00 
CAKUT 14.3 % 6.7 % 0.32 
Epilepsy 22.7 % 17.8 % 0.63 
Gastrointestinal Anomalies 30.4 % 37.8 % 0.55 
JIA/RA 8.6 % 2.2 % 0.22 
Thyroiditis 21.7 % 22.2 % 0.96 
Psoriasis 4.3 % 6.7 % 0.70 
Severe Infections 27.3 % 37.2 % 0.42 
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